United Therapeutics - UTHR Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued twelve-month price objectives for United Therapeutics' stock. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they predict the company's share price to reach $283.64 in the next twelve months. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $278.09 on January 1st, 2023. Since then, UTHR stock has decreased by 8.3% and is now trading at $255.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.37 by $0.05. The biotechnology company earned $444.70 million during the quarter, compared to the consensus estimate of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $3.84 EPS.

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.32%), Poplar Forest Capital LLC (0.33%), Wedge Capital Management L L P NC (0.31%), Retirement Systems of Alabama (0.29%), Allspring Global Investments Holdings LLC (0.27%) and Tobam (0.24%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTHR stock can currently be purchased for approximately $255.10.

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $11.63 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis.

The company employs 965 workers across the globe.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.